Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Missing CAPA Costs J&J $25 Million In Investigation Sparked By OTC Recalls

Mar 11 2015

• By Malcolm Spicer

Related Content

J&J’s <em>Mylanta</em>, <em>Mylicon</em> Lines Return Via ‘Fixed-Term’ License With Infirst

Mar 06 2015

Perrigo Applies Crime Scene Investigation Model To Improve Quality Control

Oct 17 2011

J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition

Oct 31 2014

Related Companies

Johnson & Johnson

Johnson & Johnson

Johnson & Johnson

Perrigo Company PLC

Additional Topics

United States Business Strategies Advertising, Marketing & Sales Manufacturing Drug Approval Standards Regulation Recalls Post Market Regulation & Studies Quality Compliance Approvals OTC Drugs Consumer

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window